Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States

about

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States

Item

http://www.wikidata.org/entity/Q35957567

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@ast

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@en

type

Item

label

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@ast

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@en

prefLabel

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@ast

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@en

P1476

Bortezomib Inpatient Prescribi ...... Hospitals in the United States

@en

P2093

Amanda M DiNofia

http://www.w3.org/2001/XMLSchema#string

Brian T Fisher

http://www.w3.org/2001/XMLSchema#string

Elizabeth Salazar

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

Rochelle Bagatell

http://www.w3.org/2001/XMLSchema#string

Yimei Li

http://www.w3.org/2001/XMLSchema#string

Yuan-Shung Vera Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.

Bortezomib use in a pediatric cardiac transplant center.

Bortezomib for refractory autoimmunity in pediatrics.

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.

Proteasome inhibition in hematologic malignancies.

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)

P304

e0151362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0151362

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alix E Seif

P577

2016-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298420451

http://www.w3.org/2001/XMLSchema#string

P698

26978062

http://www.w3.org/2001/XMLSchema#string

P932

4792468

http://www.w3.org/2001/XMLSchema#string